Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
about
A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signatureExciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaMedical management of brain tumors and the sequelae of treatment.Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Salvage therapy with single agent bendamustine for recurrent glioblastoma.Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent gliomaBiological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.Scale to predict survival after surgery for recurrent glioblastoma multiformeIntracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survivalStratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomasRecurrent malignant gliomas.The potential role of exercise in neuro-oncologyImaging descriptors improve the predictive power of survival models for glioblastoma patientsAppraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluationBoron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases.Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor.Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experienceIs surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practicesFDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical articleBoron Neutron Capture Therapy for Malignant Brain TumorsBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignanciesQuality of life in adults with brain tumors: current knowledge and future directionsTumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.Bevacizumab in glioblastoma multiforme.Second surgery for recurrent glioblastoma: advantages and pitfalls.
P2860
Q21560781-98249841-1AA9-48CD-B613-DBDFB829746CQ24632791-A60567C5-B1F9-4579-9461-1FE8F96FFD83Q26992174-B6DFF1F5-1088-4CD1-B654-4120234B0FACQ30429169-B9E28217-4907-41D4-8F1E-F79AB6F213E0Q30493217-30DDFC6E-C3C4-481F-82A1-145BBFA603FDQ33346827-F6C9FEB7-CA34-487B-A02F-1C54ABA6B046Q33388541-05B63ADD-7884-4DE3-9B49-681FF36A2389Q33395579-0C6AE3FB-F16E-4901-858C-8E1E929222FBQ33530811-BF97BB9B-C0E3-44E7-B708-D748D2F1BC04Q33618479-6A9B9EE1-B08B-49C6-8F89-35A151682D78Q33973844-93C742E2-5917-4D9A-B6A9-47DF5DBA6E3CQ34131832-5B95BD02-5FC3-4356-A838-4EC233961112Q34132839-930E069F-6C0B-4EAC-A7F1-BACBC4C8D04DQ34260206-7B205A76-E080-4F51-A30C-F6142785FB1AQ34260758-DED5454C-93A4-4A45-A756-A98AAD3F238EQ34315691-550CF717-045B-42D6-AC1E-49998A6C3D67Q34438507-9AD06B11-1198-4B6A-93CD-B789A2103E93Q34473328-FD5D4DAD-77DB-49B4-9B82-7C83FEB5146FQ34581866-5142F20B-B964-46EF-A2EC-F8F2DD937067Q34840438-7A8B64EE-4B49-48D5-B61D-C236341052B9Q35081479-C70D32AA-7B51-4956-8FC2-BAA432DB039FQ35112333-CF5875A5-C724-42E5-BC5A-15260A4ED23AQ35206228-302FB435-89C7-4BCD-91D6-980C9D68666DQ35206255-26B1D727-AD40-4254-9FCE-730B6AE484A2Q35225287-610FF9C8-6BAD-4284-99E2-C33B0147A156Q35621495-20098B5F-619D-4894-9EF2-CEF9293398A9Q35914501-DB8E4930-85B6-46C8-9972-8F1A08CAE1C6Q36032533-42E4035D-BB2A-4ACF-B0AF-37CB2AAC5CD4Q36367414-4FF6B5EA-2C2A-47EF-918E-62907E31D6AFQ36866038-2EE6A329-0D01-471C-883D-AFCBC182F74DQ37052309-45AF7CB1-28CA-4302-ADF7-2E58B5B3A80AQ37095894-92563A55-2F6F-4821-B4EA-BECF50BC7E9CQ37180426-1A61EE1E-E26F-4413-8C83-BDFDA616F94EQ37187292-7B192448-D6F2-43BB-B35A-8B0668184986Q37230020-83559D49-BFED-46A0-AA3D-7107E3B91FF0Q37284281-3B2ADAAA-CB9D-49C3-9292-A0E2D59AA385Q37594926-2DDB115A-D5FC-4E57-A08C-2AB2C2E86F19Q37699429-0C5982ED-F29E-44AA-86EF-1CF5C521A57CQ37965628-7129469C-00D8-4F5B-B0EF-BDA80136E861Q38101609-690C13F0-3B9E-4888-9F62-B676E90E8AE1
P2860
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prognostic factors for surviva ...... phase I and II clinical trials
@ast
Prognostic factors for surviva ...... phase I and II clinical trials
@en
Prognostic factors for surviva ...... hase I and II clinical trials.
@nl
type
label
Prognostic factors for surviva ...... phase I and II clinical trials
@ast
Prognostic factors for surviva ...... phase I and II clinical trials
@en
Prognostic factors for surviva ...... hase I and II clinical trials.
@nl
prefLabel
Prognostic factors for surviva ...... phase I and II clinical trials
@ast
Prognostic factors for surviva ...... phase I and II clinical trials
@en
Prognostic factors for surviva ...... hase I and II clinical trials.
@nl
P2093
P2860
P356
P1476
Prognostic factors for surviva ...... phase I and II clinical trials
@en
P2093
Edward G Shaw
Joy D Fisher
Kathryn A Carson
Stuart A Grossman
P2860
P304
P356
10.1200/JCO.2006.08.1661
P407
P577
2007-06-01T00:00:00Z